Rationalizing Kinase Inhibitor Combinations with Immunotherapy to Optimize Tumor Killing

Time: 12:00 pm
day: Day Two


  • Harnessing the patients’ immune systems with novel kinase inhibitors to minimize side effects
  • Assessing the key take-aways from PI3K-PD-1 dual blockade to expand to other kinase inhibitors and checkpoint inhibitors
  • Theorizing the potential for novel kinase inhibitors to act on checkpoint inhibitor resistant cancer types